RESCUE ROCKS! 2025 TOUR FOR LIFE® KICKS OFF COAST-TO-COAST ROADTRIP TO SHINE A LIGHT ON ANIMAL RESCUE & ADOPTION
North Shore Animal League America Launches 25th Annual Tour For Life®, The World's Largest Cooperative Pet Adoption Event Highlighting Lifesaving Work of Shelter Partners Nationwide
NEW YORK, Feb. 28, 2025 /PRNewswire/ -- Rescue Rocks! With a tour itinerary booked through mid-April, North Shore Animal League America's Tour For Life® - the world's largest cooperative mobile pet adoption event – will bring awareness to the plight of homeless animals, encourage pet adoption, and celebrate the incredible rescue work done by shelters and rescue organizations across the country.
North Shore Animal League America - the world's largest no-kill animal rescue and adoption organization - is kicking off their 25th annual Tour For Life®, sponsored by Lifeproof™ with Petproof™ Technology, an exclusive brand of The Home Depot, and made possible with support from Nutrish™. The route will feature adoption events in collaboration with shelter and rescue partners in 67 cities/towns in 37 states.
Animal League America's Mobile Adoption Unit will be traversing the country helping shelter partners showcase their animals at adoption events nationwide. Lifeproof™ with Petproof™ Technology, an exclusive brand of The Home Depot, will have a customized Airstream trailer and glass truck on the road at several locations as well.
"We're very proud of this milestone that has resulted in tens of thousands of animals being saved and placed into homes nationwide as well as raising awareness about the importance of rescue and adoption since we launched Tour For Life in 2001," said Joanne Yohannan, SVP., Operations, North Shore Animal League America. "Tour For Life is our chance to celebrate the rock stars working tirelessly behind-the-scenes (at Animal League America and our shelter partners) with one shared goal: save animals' lives and find them loving homes. We remain focused on innovations and excellence to further our no-kill, lifesaving mission."
A cornerstone initiative of Animal League America, the goal of Tour For Life is to highlight and celebrate the life-saving work of local rescue groups and shelters nationwide and stress the importance of adoption – not only of kittens and puppies, but of older cats and dogs, as well as animals with special needs.
For more information about Tour For Life 2025 and a list of shelter partners participating nationwide, visit : www.animalleague.org/TourForLife
For media assets visit 2025 TOUR FOR LIFE MEDIA ASSETS ** Credit: North Shore Animal League America**
For more information on our life-saving work, including adoption, pet health & wellness, volunteering, and donations please visit www.animalleague.org
Media Contact: KATHLEEN LYNN Senior Director of Communications Phone: (516) 528-7878 Email: KathleenL@animalleague.org
About NORTH SHORE ANIMAL LEAGUE AMERICANorth Shore Animal League America has saved more than 1.2 Million lives. As the world's largest no-kill rescue and adoption organization, we understand that a rescue isn't complete until each animal is placed into a loving home. Our innovative programs provide education to reduce animal cruelty and advance standards in animal welfare. Our staff and volunteers work tirelessly in the pursuit of our vision of a world where all companion animals find permanent homes and end the euthanasia. For more information, visit www.animalleague.org
About LIFEPROOF™ WITH PETPROOF™ TECHNOLOGY CARPETLifeproof™ with Petproof™ Technology carpet can be found exclusively at The Home Depot. The carpet is designed to stand up to any household pet mess with superior comfort, style, cleanability, and durability. When purchased with the Lifeproof carpet pad, the carpet is backed by a lifetime stain, wear, and installation warranty. Lifeproof with Petproof™ Technology carpet is the worry-free choice for pet parents and busy families. For more information, visit homedepot.com/petproofcarpet
About NUTRISH™Nutrish™ is a leading brand in the Post Consumer Brands pet food and snacks portfolio. Nutrish offers specially crafted dog and cat food and snacks recipes featuring high-quality ingredients and backed by our team of nutrition and dog and cat experts. With every Nutrish purchase, a portion of the sale's proceeds is donated to The Rachael Ray Foundation, which funds charitable organizations supporting local communities through animal rescue, fostering, adoptions, medical care, and supplies for animals in need. To learn more about Nutrish, visit nutrish.com
TWITTER @animalleague.orgINSTAGRAM @animalleague.orgFACEBOOK North Shore Animal League AmericaTIK TOK @animalleagueHashtags #GetYourRescueOn #TourForLife
View original content to download multimedia:https://www.prnewswire.com/news-releases/rescue-rocks-2025-tour-for-life-kicks-off-coast-to-coast-roadtrip-to-shine-a-light-on-animal-rescue--adoption-302388865.html
SOURCE North Shore Animal League America
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Verge
18 minutes ago
- The Verge
Posted Jun 11, 2025 at 4:51 PM EDT 0 Comments
Google has appointed a chief AI architect. Koray Kavukcuoglu, Google DeepMind's chief technology officer, will work to combine Google's AI models with its products 'with the goal of more seamless integration, faster iteration, and greater efficiency,' according to a memo seen by Semafor. Kavukcuoglu will reportedly remain Google DeepMind CTO while in his new role.
Yahoo
37 minutes ago
- Yahoo
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), held its Combined General Meeting (the 'General Meeting'). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company's shareholders approved all resolutions submitted by the Board of Directors. The resolutions and the voting results are posted on the Investors/Annual General Meetings section of the Company's website: About DBV TechnologiesDBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin™, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Viaskin and EPIT are trademarks of DBV Technologies. Investor Contact Katie MatthewsDBV Media ContactAngela Marcucci DBV Attachment PDF VersionFehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
an hour ago
- Yahoo
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split
OCALA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) ('AIM' or the 'Company') today announced a reverse stock split ('Reverse Stock Split') of its shares at a ratio of 1-for-100. The Reverse Stock Split will take effect at market open tomorrow, June 12, 2025. The Company's ticker symbol on the OTC Pink will be AIMID for 20 trading days, including the effective date. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company's common stock to enable the Company to regain compliance with the NYSE American's Listing Qualifications. At a Special Meeting of Stockholders held on April 30, 2025, the Company's stockholders approved a series of alternate amendments to the Company's Certificate of Incorporation to effect a reverse stock split of the Company's outstanding common stock at a ratio in the range of up to 1-for-100, with such ratio to be determined by the Company's Board of Directors. Stockholders will be given cash in lieu of any fractional shares on a post-split basis. Following the Reverse Stock Split, the new CUSIP number of the common stock will be 00901B303, with the par value per share of common stock remaining at $0.001. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the 'PSLRA'). Words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'continue,' 'believe,' 'potential,' 'upcoming' and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@
